Veru Stock News

--ENTADFI (Finasteride and Tadalafil) Capsules to Treat Benign Prostatic Hyperplasia-- --Commercialization Will Start Early Calendar Year 2022--

Morgan Stanley decreased its position in Veru Inc. (NASDAQ:VERU) by 61.4% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 400,279 shares of the companys stock after selling 636,898 shares during the period. Morgan Stanleys holdings in Veru were worth $3,231,000 at the end of the most []

MIAMI, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast cancer and prostate c

MIAMI, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast cancer and prostate cancer, today announced that human preclinical data will be presented demonstrating that enobosarm treatment alone as well as in combination with a CDK4/6 inhibitor increased androgen receptor (AR) expression resulting in the synergistic suppression of breast cancer cell and tumor models that are resistant to CDK4/6 inhibitors and estrogen blocking agents. Enobosarm is an oral, first-in-class, selective androgen receptor targeted agonist for the androgen receptor, a tumor suppressor, being evaluated in Phase 3 clinical studies to treat AR+ER+HER2- metastatic breast cancer without unwanted masculinizing side effects. The presentation was selected as a spotlight presentation at the San Antonio Breast Cancer Symposium being held December 07-10, 2021, in San Antonio, TX.

HC Wainwright reaffirmed their buy rating on shares of Veru (NASDAQ:VERU) in a research note released on Friday morning, Analyst Ratings Network reports. The firm currently has a $20.00 target price on the stock. Several other equities analysts have also commented on VERU. Oppenheimer restated a buy rating and set a $26.00 price target on []

Equities research analysts predict that Veru Inc. (NASDAQ:VERU) will report earnings per share of ($0.07) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Verus earnings, with the highest EPS estimate coming in at ($0.05) and the lowest estimate coming in at ($0.09). Veru posted earnings of ($0.02) per share during []

Equities research analysts expect that Veru Inc. (NASDAQ:VERU) will announce sales of $19.00 million for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Verus earnings, with estimates ranging from $18.00 million to $20.00 million. Veru reported sales of $14.62 million during the same quarter last year, which suggests a []

Veru (NASDAQ:VERU) issued its earnings results on Thursday. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the Zacks consensus estimate of ($0.09) by $0.04, MarketWatch Earnings reports. Veru had a negative net margin of 0.25% and a negative return on equity of 7.62%. During the same period in the previous year, []

Veru, Inc. (VERU) CEO Mitchell Steiner on Q4 2021 Results - Earnings Call Transcript

A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for the year-to-date peri

Veru Inc. (VERU) delivered earnings and revenue surprises of 37.50% and 14.32%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

--FY21 Net Revenues Increase 44% to $61 Million and Gross Profit Increases 56% to $48 Million, Achieving New Historical Highs-- --Phase 3 Sabizabulin COVID-19 Clinical Study for Treatment of Hospitali

--FY21 Net Revenues Increase 44% to $61 Million and Gross Profit Increases 56% to $48 Million, Achieving New Historical Highs-- --Phase 3 Sabizabulin COVID-19 Clinical Study for Treatment of Hospitalized Moderate to Severe COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome Being Conducted in US, Mexico, South America, and Europe; Clinical Results Expected 1H 2022--